US FDA pushes decision on Moderna’s RSV vaccine to end of this month
The U.S. drug regulator has pushed back its decision on Moderna’s (MRNA.O) respiratory syncytial virus (RSV) vaccine due to “administrative constraints” and will complete the review by the end of this month, the company said on Friday.